LIBRARY DESIGN FOR COLLABORATIVE DRUG DISCOVERY: EXPANDING DRUGGABLE CHEMOGENOMIC SPACE

Similar documents
Progress of Compound Library Design Using In-silico Approach for Collaborative Drug Discovery

Introduction. OntoChem

MSc Drug Design. Module Structure: (15 credits each) Lectures and Tutorials Assessment: 50% coursework, 50% unseen examination.

Cheminformatics Role in Pharmaceutical Industry. Randal Chen Ph.D. Abbott Laboratories Aug. 23, 2004 ACS

Chemical Data Retrieval and Management

Computational Chemistry in Drug Design. Xavier Fradera Barcelona, 17/4/2007

AMRI COMPOUND LIBRARY CONSORTIUM: A NOVEL WAY TO FILL YOUR DRUG PIPELINE

Using AutoDock for Virtual Screening

Introduction to Chemoinformatics and Drug Discovery

Structural biology and drug design: An overview

Chemogenomic: Approaches to Rational Drug Design. Jonas Skjødt Møller

October 6 University Faculty of pharmacy Computer Aided Drug Design Unit

Machine learning for ligand-based virtual screening and chemogenomics!

Biologically Relevant Molecular Comparisons. Mark Mackey

In Silico Investigation of Off-Target Effects

De Novo molecular design with Deep Reinforcement Learning

Design and Synthesis of the Comprehensive Fragment Library

Building innovative drug discovery alliances

Introduction to Chemoinformatics

Receptor Based Drug Design (1)

Expanding the scope of literature data with document to structure tools PatentInformatics applications at Aptuit

The Molecule Cloud - compact visualization of large collections of molecules

How IJC is Adding Value to a Molecular Design Business

Drug Informatics for Chemical Genomics...

Computational chemical biology to address non-traditional drug targets. John Karanicolas

Structure-based maximal affinity model predicts small-molecule druggability

Capturing Chemistry. What you see is what you get In the world of mechanism and chemical transformations

Navigating between patents, papers, abstracts and databases using public sources and tools

Synthetic organic compounds

Dr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre

Data Quality Issues That Can Impact Drug Discovery

In silico pharmacology for drug discovery

Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining

Early Stages of Drug Discovery in the Pharmaceutical Industry

Chemical library design

Retrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a

Hit Finding and Optimization Using BLAZE & FORGE

Supporting Information

Structure Investigation of Fam20C, a Golgi Casein Kinase

Kinome-wide Activity Models from Diverse High-Quality Datasets

Virtual affinity fingerprints in drug discovery: The Drug Profile Matching method

Open PHACTS Explorer: Compound by Name

Dispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses

Medicinal Chemist s Relationship with Additivity: Are we Taking the Fundamentals for Granted?

Introducing a Bioinformatics Similarity Search Solution

György M. Keserű H2020 FRAGNET Network Hungarian Academy of Sciences

TRAINING REAXYS MEDICINAL CHEMISTRY

COMBINATORIAL CHEMISTRY: CURRENT APPROACH

Use of data mining and chemoinformatics in the identification and optimization of high-throughput screening hits for NTDs

Supporting Information

The Changing Requirements for Informatics Systems During the Growth of a Collaborative Drug Discovery Service Company. Sally Rose BioFocus plc

Building innovative drug discovery alliances. Just in KNIME: Successful Process Driven Drug Discovery

Navigation in Chemical Space Towards Biological Activity. Peter Ertl Novartis Institutes for BioMedical Research Basel, Switzerland

JCICS Major Research Areas

bcl::cheminfo Suite Enables Machine Learning-Based Drug Discovery Using GPUs Edward W. Lowe, Jr. Nils Woetzel May 17, 2012

Targeting protein-protein interactions: A hot topic in drug discovery

FRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC )

COMBINATORIAL CHEMISTRY IN A HISTORICAL PERSPECTIVE

Relative Drug Likelihood: Going beyond Drug-Likeness

Virtual screening in drug discovery

The Institute of Cancer Research PHD STUDENTSHIP PROJECT PROPOSAL

CADASTER & MC ITN ECO

Reaxys Medicinal Chemistry Fact Sheet

FRAUNHOFER IME SCREENINGPORT

CH MEDICINAL CHEMISTRY

Computational Methods and Drug-Likeness. Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004

PubChem data extraction and integration using Instant JChem. Oleg Ursu Cristian Bologa Tudor I. Oprea Division of Biocomputing

Synthetic organic compounds

Bioengineering & Bioinformatics Summer Institute, Dept. Computational Biology, University of Pittsburgh, PGH, PA

A Tiered Screen Protocol for the Discovery of Structurally Diverse HIV Integrase Inhibitors

est Drive K20 GPUs! Experience The Acceleration Run Computational Chemistry Codes on Tesla K20 GPU today

QSAR Modeling of ErbB1 Inhibitors Using Genetic Algorithm-Based Regression

Structure-Based Drug Discovery An Overview

Applications of Fragment Based Approaches

An Integrated Approach to in-silico

Next Generation Computational Chemistry Tools to Predict Toxicity of CWAs

Enamine Golden Fragment Library

Ignasi Belda, PhD CEO. HPC Advisory Council Spain Conference 2015

COMPUTERS IN PHARMACEUTICAL RESEARCH & DEVELOPMENT

Practical QSAR and Library Design: Advanced tools for research teams

DRUG DISCOVERY TODAY ELN ELN. Chemistry. Biology. Known ligands. DBs. Generate chemistry ideas. Check chemical feasibility In-house.

What is a property-based similarity?

Important Aspects of Fragment Screening Collection Design

Plan. Day 2: Exercise on MHC molecules.

EMPIRICAL VS. RATIONAL METHODS OF DISCOVERING NEW DRUGS

Chemical Space. Space, Diversity, and Synthesis. Jeremy Henle, 4/23/2013

Virtual Screening Strategies in Drug Discovery: A Critical Review

Can we estimate the accuracy of ADMET predictions?

ESPRESSO (Extremely Speedy PRE-Screening method with Segmented compounds) 1

Keywords: anti-coagulants, factor Xa, QSAR, Thrombosis. Introduction

ChemBioNet: Chemical Biology supported by Networks of Chemists and Biologists. Affinity Proteomics Meeting Alpbach. Michael Lisurek 15.3.

Protein structure based approaches to inhibit Plasmodium DHODH for malaria

Supporting Information (Part II) for ACS Combinatorial Science

Drug Design 2. Oliver Kohlbacher. Winter 2009/ QSAR Part 4: Selected Chapters

EATRIS European Advanced Translational Research Infrastructure in Medicine. 2

Reactive Fluid Dynamics 1 G-COE 科目 複雑システムのデザイン体系 第 1 回 植田利久 慶應義塾大学大学院理工学研究科開放環境科学専攻 2009 年 4 月 14 日. Keio University

Ping-Chiang Lyu. Institute of Bioinformatics and Structural Biology, Department of Life Science, National Tsing Hua University.

Welcome to Week 5. Chapter 9 - Binding, Structure, and Diversity. 9.1 Intermolecular Forces. Starting week five video. Introduction to Chapter 9

Cross Discipline Analysis made possible with Data Pipelining. J.R. Tozer SciTegic

Genetic Mutations. Jing Lu

Transcription:

5 th /June/2018@British Embassy in Tokyo LIBRARY DESIGN FOR COLLABORATIVE DRUG DISCOVERY: EXPANDING DRUGGABLE CHEMOGENOMIC SPACE Kazuyoshi Ikeda, Ph.D. Keio University

SELF-INTRODUCTION Keio University, Faculty of Pharmacy ( 慶應義塾大学薬学部生命機能物理学研究室 ) Bio/Chemo-informatics in-silico drug discovery Library design (a part of AMED project) Structural Biology (NMR, Prof.Osawa) Onarimon ( 御成門 ), Tokyo Near Zouzyougi Temple ( 増上寺 )

TODAY S TOPICS Ø Background: Comparison of Compound Libraries Ø Library Design Informatics Using Drug Discovery Data and Virtual Compounds Ø Collaborative Drug Discovery May Expand Druggable Chemical Space

CHEMICAL SPACE IS VAST Reymond JL. & Awale M., ACS Chem Neurosci. (2012) 19;3:649-657. Number of stars in our galaxy: 10 12 Estimated size of small molecule chemical space: >10 12

IMPACT OF OPEN SCREENING DATA Drug Discovery Data Resources #Activities and Compounds by Year HTS or Screening Literature in ChEMBL ü >50% from non-literature data ü HTS data is rapidly increasing by open drug discovery projects

SIZE OF PUBLIC CHEMICAL DATABASES 10-12 10-9 10-7 10-6 10-5 10-4 GDB17-160 Billion organic small compounds PubChem - 96M HTS screening cmpds incl. inactivies SureChem - 16 Million patent compounds ChEMBL (ver24) -1.8 Million bioactive compounds BindingDB -65K binding molecules to structures DrugBank -10K approved drugs

LIMITED BIOACTIVE SPACE ALogP Small Drugs vs Natural Products Ro5 Ro5 PPI Inhibitors Ro4 Beyond Ro5 MW ü 85% of approved small molecule drugs within Lipinski s Ro5 space MW ü Only half of PPI Inhibitors are within Ro5. ü Rule of 4 covers over 90% of those.

Mapping Virtual Rings on Patent Compounds NIH-MLSMR Library 489 ChEMBL Unpatented Bioactive Compounds 931 (45 Rings) VEHICLe (virtual exploratory heterocyclic SureChem (Patent) 2,072 library) 24,807 Rings

Library Design Protocol Using Patent & Virtual Cmpds -DATA EXTRACTIONü Mechanism of Action ü Target Information ü Activity Type & Value -3D-SAR Modelingü 3D-Alignment -Focused-Library Generationü Scaffold Hopping based on Electrostatic similarity. patent/bioactive virtual ü 3D-QSAR Model Predicition

Phosphodiesterase 5A inhibitor (VIAGRA) with Patent & Bioactive 1. SILDENAFIL 3. VERDENAFIL Sildenafil Electrostatic Surface New Structures ü Starting from Sildenafil, various scaffolds are generated by the similarity of electrostatic interaction surfaces. ü a library of compounds with the similar bioactivity is designed. Possible Promising Structures

A Protein Try-Kinase (B-RAF) with Virtual Structural Alert Filter B-RAF in complex with Dabrafenib (5csw) 3D SAR Prediction Druglikeness Novel Structure Library

COLLABORATIVE DRUG DISCOVERY

LIBRARY SHARING B/W ASTRAZENECA-BAYER Big pharma screening collections: More of the same or unique libraries? the AstraZeneca- Bayer Pharma AG case (2013) ü Most compounds between AZ and BYR with similarity of less than 0.7.

LILLY S OPEN INNOVATION PROGRAM Max_Tanimoto < 0.9 or 0.85 Lilly collects compounds which didn t exist in their library from >300 external collaborators via secure informatics system. Total over 50K compounds tested including hits/leads for different targets. Open Innovation Drug Discovery (OIDD): A Potential Path to Novel Therapeutic Chemical Space., Alvim-Gaston M, et al. Current Topics in Medicinal Chemistry 2014 vol: 14 pp: 294-303

CHEMICAL SPACE COMPLEMENT ü Their original library was complemented with unique compounds that fill the gaps (disk-like).

CONTEST-BASED IN SILICO SCREENING

CONCEPT OF IPAB-CONTEST A non-profit organization, IPAB (Initiative for PArallel Bioinformatics) and Tokyo Institute of Technology ( 東工大 ) organizes an open CADD contest. N-lobe Gate Keeper Gly loop Hing Region P-loop Activation Segegment (DFG motif) Catalytic Loop 10 teams joined to predict inhibitors for a Tyr Kinase (cyes) using different computational methods applied. Assays were performed to confirm the submitted compound s activities later. C-lobe www.ipab.org/eventschedule/contest/contest3

IPAB CONTEST RESULT chiba et al. scientific reports (2016, 2017)

SUMMARIES Ø The understanding of the chemical space is important for designing efficient compound libraries. Ø A library design informatics approach using drug discovery data and virtual compounds generates a drug-like focused library with novel structures. Ø Collaborative drug discovery and informatics method may contribute to expand druggable chemical space.

ACKNOWLEDGEMENT Keio University Prof. Masanori Osawa Dr. Yugo Shimizu Special Thanks to Ikegami-san & Marcus